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Abstract
Chronic myelogenous leukaemia (CML) is a clonal myeloproliferative disorder. Recent evidence indicates that altered crosstalk between CML
and mesenchymal stromal cells may affect leukaemia survival; moreover, vesicles released by both tumour and non-tumour cells into the
microenvironment provide a suitable niche for cancer cell growth and survival. We previously demonstrated that leukaemic and stromal cells
establish an exosome-mediated bidirectional crosstalk leading to the production of IL8 in stromal cells, thus sustaining the survival of CML
cells. Human cell lines used are LAMA84 (CML cells), HS5 (stromal cells) and bone marrow primary stromal cells; gene expression and protein
analysis were performed by real-time PCR and Western blot. IL8 and MMP9 secretions were evaluated by ELISA. Exosomes were isolated from
CML cells and blood samples of CML patients. Here, we show that LAMA84 and CML patients’ exosomes contain amphiregulin (AREG), thus
activating epidermal growth factor receptor (EGFR) signalling in stromal cells. EGFR signalling increases the expression of SNAIL and its tar-
gets, MMP9 and IL8. We also demonstrated that pre-treatment of HS5 with LAMA84 exosomes increases the expression of annexin A2 that pro-
motes the adhesion of leukaemic cells to the stromal monolayer, finally supporting the growth and invasiveness of leukaemic cells. Leukaemic
and stromal cells establish a bidirectional crosstalk: exosomes promote proliferation and survival of leukaemic cells, both in vitro and in vivo,
by inducing IL8 secretion from stromal cells. We propose that this mechanism is activated by a ligand–receptor interaction between AREG,
found in CML exosomes, and EGFR in bone marrow stromal cells.
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Introduction
Chronic myelogenous leukaemia (CML) is a clonal myeloproliferative
disorder characterized by the reciprocal t (9:22) chromosomal
translocation that results in the Philadelphia (Ph) chromosome
encoding the chimeric Bcr–Abl oncoprotein [1]. Bcr–Abl shows a con-
stitutive tyrosine kinase activity that drives disease progression by
stimulating a number of downstream signalling pathways [2].
Because of its critical role in CML pathogenesis, most therapies have
focused on targeting Bcr–Abl [3]. These conventional therapies, such
as imatinib or second- and third-generation inhibitors (dasatinib or
nilotinib), induce molecular remission in most patients; however, a
number of investigations have demonstrated the persistence of a leu-
kaemic stem cell pool in the bone marrow (BM) niche even after ima-
tinib treatment [4]. Recent evidence indicates that altered crosstalk
between mesenchymal stromal cells and CML cells may affect leukae-
mia cell survival and resistance to chemotherapy [5, 6]. For these rea-
sons, new studies have shifted the focus on the role of cytokines,
growth factors, adhesion molecules released by both tumour and
non-tumour cells into the microenvironment that provide a suitable
niche for cancer cell growth and survival. In this context, exosomes
are now considered as new actors in regulating tumour microenviron-
ment [7, 8].
Exosomes are nanovesicles of 40–100 nm diameter that are
formed within the endosomal compartment and secreted when a mul-
tivesicular body (MVB) fuses with the plasma membrane [9]. We have
recently shown that cancer-derived exosomes modulate the crosstalk
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between leukaemia cells and the bone marrow microenvironment; in
particular, we have reported that CML cells release exosomes and that
the addition of these vesicles to vascular endothelial cells as well as
to bone marrow stromal cells affects both in vitro and in vivo tumour
progression, through the stimulation of an interleukin 8-mediated
paracrine and autocrine loops [10–13].
Different studies suggest that epidermal growth factor receptor
(EGFR) ligands regulate autocrine and/or paracrine signalling induc-
ing the activation of EGFR targets such as early-growth response-1
that drives stromal cells to produce several cytokines or growth fac-
tors that regulate cell proliferation, migration and apoptosis [14, 15].
Moreover, EGFR ligands, such as amphiregulin (AREG), are able to
activate EGFR, in a paracrine or autocrine way, thus enhancing
tumour cell aggressiveness and chemoresistance and contributing to
the transformed phenotype [16–18]. Singh and Coffey recently pro-
posed the extracrine (exosomal-targeted receptor activation) sig-
nalling that involves the packaging and release of EGFR ligands via
exosomes [19]. Coffey’s group demonstrated that tumour exosomes,
carrying the EGFR ligand AREG, are rapidly internalized in recipient
human breast and colorectal cancer cells thus increasing cancer cell
invasion [20]. AREG can be considered a multicrine signalling protein,
involved in evading apoptosis and sustaining angiogenesis, tissue
invasion and metastasis [17, 21, 22]. Here, we show that CML exo-
somes, carrying AREG, are able to activate EGFR signalling in stromal
cells leading to increased IL8 expression and secretion [12].
Annexin A2 is a pleiotropic protein involved in the regulation of
different cellular processes, such as cellular growth, cell adhesion
and motility. Recently, it has been demonstrated that annexin A2,
expressed on stromal cells, regulated bone marrow homing of Multi-
ple Myeloma cells supporting their growth and regulating their adhe-
sion to stromal cells [23]. We demonstrated that the pre-treatment of
HS5 cells with LAMA84 exosomes increases the expression of
annexin A2 mRNA and protein and the adhesion of leukaemic cells to
the stromal monolayer, thus sustaining the growth, survival and inva-
siveness of CML cells [12].
In conclusion, we showed that chronic myelogenous leukaemia
cell-derived exosomes modulate bone marrow microenvironment
through activation of EGFR in stromal cells. These results may have
significant implications for new therapeutic approaches involving exo-
somes and their specific content for early diagnosis of chronic myel-
ogenous leukaemia.
Materials and methods
Cell culture and reagents
Chronic myeloid leukaemia cell line, LAMA84, was obtained from DSMZ
(Braunschweig, Germany); human primary CD34+ cells and bone mar-
row primary stromal cells (BMSCs) were obtained from Lonza (Basel,
Switzerland). LAMA84 cells were cultured in RPMI 1640 medium, sup-
plemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin and 100 lg/ml streptomycin (Euroclone, UK). CD34+
cells were cultured in IMDM medium, supplemented with 15% FBS,
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin
(Euroclone, UK). BMSCs were cultured in MyeloCult H5100 (STEMCELL
Technologies Inc., Vancouver, BC, Canada). Gefitinib or Erlotinib (Cay-
man Chemical, Ann Arbor, MI, USA) was solubilized at 10-mM stock
solution in DMSO and stored at "20°C. Neutralizing antibody anti-AREG
(R&D Systems, Abingdon, UK) was reconstituted at 0.2 mg/ml in sterile
PBS, aliquoted and stored at "20°C. Recombinant Areg (R&D Systems,
Abingdon, UK) was reconstituted at 0.1 mg/ml in sterile PBS, aliquoted
and stored at "20°C. Working dilutions, where necessary, were pre-
pared in medium. All other reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA), if not cited otherwise.
CML patients
Blood samples were obtained from 13 newly diagnosed CML patients.
Informed consent was obtained from patients, according to the Declara-
tion of Helsinki and with hospital ethics committee approval. Whole-
blood samples were treated with red blood cell lysing buffer (Sigma, St.
Louis, MO, USA) for 2 min at room temperature and then centrifuged
at 350 g for 7 min to recover and discard lysed red cells. The inter-
phase layer containing CML cells was collected, and the cells were
resuspended in PBS and used to obtain total protein extract and to
extract RNA or cultured in RPMI complete medium as described for
LAMA84 cells. Exosomes released in fresh patient’s serum were pre-
pared as described in the section ‘Exosome isolation’.
Exosome isolation
Exosomes released by CML cells after a 24-hr culture period in the
presence of FBS previously ultracentrifuged (vesicle-free media) were
isolated from conditioned culture medium by differential centrifugation
as described by Thiery et al. [24]. Exosome pellet was washed and then
resuspended in PBS. Exosome protein content was determined by the
Bradford assay (Pierce, Rockford, IL, USA). Exosome characterization
was previously described by our group [11].
RNA extraction and real-time PCR
HS5 cells were grown in 12-well plates up to 80% confluence and treated
or not with 20–50 lg/ml of LAMA84" exosomes # Gefitinib 30 lM for
different times (30 min. to 72 h), as described in the results. Bone mar-
row primary stromal cells were grown in 12-well plates up to 80% conflu-
ence and treated or not with 50 lg/ml of LAMA84" exosomes #
Gefitinib 30 lM for different times (1–6 h), as described in the results.
RNA was extracted using the commercially available Illustra RNAspin Mini
Isolation Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK),
according to manufacturer’s instructions. Total RNA from HS5 or from
CML patient cells was reverse transcribed to cDNA using the High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA). RT-QPCR was performed in 48-well plates using the Step-One
Real-Time PCR system (Applied Biosystems). For quantitative Sybergreen
real-time PCR, reaction was carried out in a total volume of 20 ll contain-
ing 29 SYBR Green I Master Mix (Applied Biosystems), 2 ll cDNA and
300 nM forward and reverse primers. Primer sequences were as follows:
GAPDH (50ATGGGGAAGGTGAAGGTCG30, 50GGGTCATTGATG
GCAACAATAT30)
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SNAIL (50GCGAGCTGCAGGACTCTAAT30, 50CCCGCAATGGT
CCACAAAAC30)
IL8 (50GAATGGGTTTGCTAGAATGTGATA30, 50CAGACTAGGG
TTGCCAGATTTAAC30)
MMP9 (50CGCTACCACCTCGAACTTTG30, 50GCCATTCACGTCG
TCCTTAT30)
ANNEXIN A2 (50TGAGCGGGATGCTTTGAAC30¸ 50ATCCTGTCT
CTGTGCATTGCTG30)
AREG (50GTGGTGCTGTCGCTCTTGATACTC30, 50TCAAATCCA
TCAGCACTGTGGTC30)
HBEGF (50GGAACTCACTTTCCCTTGTGTC30, 50CTCAGCCTTTT
GCTTTGCTAAT30)
EREG (50GAGAAGGGGGAGTAATGACTTG30, 50AAGTGCAATTA
CAGAGTGCAAAA30)
EGF (50TGCAGAGGGATACGCCCTAA30, 50TGCGTGGACAGG
AAACAAGT30)
All were obtained from Invitrogen (Foster City, CA, USA). Real-time
PCR was performed in duplicates for each data point. Relative changes
in gene expression between control and treated samples were deter-
mined using the DDCt method. Levels of the target transcript were nor-
malized to a GAPDH endogenous control, constantly expressed in all
samples (DCt). For DDCt values, additional subtractions were per-
formed between treated samples and control DCt values. Final values
were expressed as fold of induction.
RNA interference
Small-interfering RNAs (siRNA) targeting Snail or scramble siRNA were
purchased from Dharmacon (ON-TARGET plus SMART pool, Human,
Dharmacon Inc., Lafayette, CO, USA) and used to transfect HS5 cells
by employing Lipofectamine RNAiMAX Reagent (Invitrogen, UK),
according to the suggested protocol. Briefly, 30–50% confluent cells,
plated the day before in 24 wells, were incubated with a mix of Lipofec-
tamine RNAiMAX-Opti-MEM containing 2 pmol of siRNA. After 6 h, cells
were lysed for RNA extraction. Knockdown efficiency was determined
by real-time PCR quantitation of Snail.
Western blot
HS5 cells were starved for 2 h in a serum-free medium and treated or
not for different times (30 min., 3 h, 6 h, 24 h) with LAMA84" exo-
somes (20–50 lg/ml) # gefitinib 30 lM or erlotinib 30 lM. Neutraliz-
ing antibody anti-AREG (20 ng/ml) was incubated with LAMA84
exosomes (50 lg/ml) for 2 h at 37°C and then used to treat HS5 for
3 h. Bone marrow primary stromal cells were treated or not for different
times (30 min., 18 h) with LAMA84" exosomes (50 lg/ml) # gefitinib
30 lM. Total protein lysates were obtained at the end of each treat-
ment. Protein lysates from LAMA84 cells, from CML patients cells, from
HS5, from BMSC, from exosomes or from conditioned medium of
LAMA84 cells were analysed by SDS-PAGE in reducing conditions fol-
lowed by Western blotting as previously described [6]. Antibodies used
in the experiments were as follows: anti-EGFR, pEGFR, annexin A2 and
b-actin (all from Cell Signalling Technology, Lane Danvers, MA, USA);
anti-SNAIL and MMP9 (all from Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and anti-AREG (R&D systems, Abingdon, UK).
ELISA assay
HS5-conditioned medium (CM) was collected from cells stimulated or not
for 12–24 h with LAMA84 exosomes (20–50 lg/ml) # 30 lM gefitinib.
BMSC-CM was collected from cells stimulated or not for 6 h with
LAMA84" exosomes (50 lg/ml) # 30 lM gefitinib. CM aliquots were
centrifuged to remove cellular debris and used to quantify IL8 or MMP9
with ELISA kits according to the manufacturer’s protocol (R&D Systems,
Abingdon, UK, for IL8; Cloud-Clone Corp., Houston, TX, USA, for MMP9).
Adhesion assay
Adhesion assay was performed as previously described by our group [12].
Briefly, HS5 monolayer was incubated for 24 h with 50 lg/ml LAMA84"
exosomes # gefitinib (1–5–10 lM). After treatments, cells were washed
with PBS, fixed and CML cells were added for 3.5 h at 37°C. Adherent cells
were stained with haematoxylin/eosin, each test group was assayed in tripli-
cate; five high power (4009) fields were counted for each condition.
Statistical analysis
Data were expressed as mean # SEMs of three independent experi-
ments. Statistical analysis was performed by using an unpaired Stu-
dent’s t-test. Differences were considered to be significant when P
values were smaller than 0.05.
Results
LAMA84 cells and CML patients release
exosomes containing AREG
In order to better understand how the addition of LAMA84"
exosomes to bone marrow stromal cells leads to the increased inter-
leukin 8 release [12], we decided to investigate the possible role of
receptor tyrosine kinases. We have observed, by RTK assay, that the
treatment of HS5 stromal cells with LAMA84" exosomes for 30 min.
induces the activation of EGFR (Fig. S1). We, therefore, investigated
the expression of EGFR ligands in LAMA84 cells, CML patients and in
their released exosomes. We determined the mRNA expression of dif-
ferent EGFR ligands on LAMA84 cells, and we found that the most
expressed EGFR ligand is AREG (Fig. S2C). Recent articles correlate
AREG to tumour cell aggressiveness and chemoresistance [16–18,
21, 22], and it has been proposed a new extracrine (exosomal-tar-
geted receptor activation) signalling that involves the packaging and
release of the EGFR ligand AREG via exosomes [20]. LAMA84 cells
and their exosomes contain Areg mRNA, but no significative differ-
ences between cells and exosomes were found (data not shown). As
shown, by Western blot, in Figure 1A, AREG is enriched in LAMA84"
exosomes with respect to LAMA84 cells. Moreover, the conditioned
medium of LAMA84 cells deprived of exosomes does not contain the
protein, thus confirming the localization of AREG in exosomes. Rela-
tively to protein content of other EGFR ligands on LAMA84 cells and
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LAMA84" exosomes, we performed the luminex assay and we found
that transforming growth factor alpha (TGF-a) is undetermined both
in cells and in exosomes, while EGF and HBEGF are found in very
small amount with a detection fold closed to the lower standard, both
in cells and in exosomes (data not shown). To confirm the presence
of EGFR ligands also in vivo, we collected blood samples from 13
newly diagnosed CML patients and extracted RNAs; the real-time PCR
showed that CML patients expressed mRNA of HBEGF, EREG and
AREG (Fig. 1B and Fig. S2A and B). Figure 1B shows, by real-time
PCR, that all patients express Areg mRNA;, moreover, eight patients
(62%) showed higher level of Areg mRNA with respect to CD34+ con-
trol cells. To confirm in vivo the packaging of AREG in exosomes, we
collected cells and exosomes from two patients to obtain total protein
lysate. As shown in Figure 1C, both patients contain the ligand in the
cells and in the exosomes. These data demonstrate the presence of
AREG in CML cells in vitro and in vivo.
LAMA84" exosomes increase EGFR
phosphorylation in HS5 stromal cells and in
bone marrow primary stromal cells
In order to confirm the functional role of exosomal AREG as signalling
molecule in stromal cells, HS5 cells were treated for 30 min. with differ-
ent concentrations of LAMA84" exosomes (20–50 lg/ml) and Gefi-
tinib, the selective inhibitor of the EGFR activation. Figure 2A and B
shows, by Western blot, that LAMA84" exosomes increase the expres-
sion of EGFR and its phosphorylation at levels comparable with the
effect of recombinant AREG, used as positive control. Co-treatment with
LAMA84" exosomes and gefitinib significantly reduces the phosphory-
lation of EGFR. These data suggest that LAMA84" exosomes trigger an
AREG-mediated activation of EGFR in HS5 stromal cells. These data
were also confirmed using bone marrow primary stromal cells (Fig. 2C).
To further endorse the effect of LAMA84" exosomes on EGFR phos-
phorylation, we performed a Western blot assay on protein extracts
from HS5 cells treated or not with LAMA84" exosomes (50 lg/ml) and
30 lM erlotinib, another inhibitor of the EGFR activation. As shown in
Figure 2D, LAMA84" exosomes increase the EGFR phosphorylation
and erlotinib partially reverts these effects.
LAMA84" exosomes increase Snail expression
in HS5 stromal cells and in bone marrow
primary stromal cells
To further investigate the involvement of EGFR signalling pathway in
exosome-mediated events, we measured the expression level of
SNAIL, a downstream target of EGFR [25,26]. For this purpose, HS5
cells were treated for different times (up to 24 h) with 50 lg/ml of
LAMA84" exosomes. As shown in Figure 3A, LAMA84" exosomes
induce a significative increase in mRNA expression of Snail after 1 h
of treatment. Treatment of HS5 cells with increasing concentration of
LAMA84" exosomes (20–50 lg/ml) confirms that 50 lg/ml of exo-
somes causes the maximum effect. Furthermore, the co-treatment of
LAMA84" exosomes with gefitinib significantly reduces the expres-
sion of Snail, at mRNA level, thus reverting the effects mediated by
LAMA84" exosomes and confirming the involvement of EGFR-
mediated pathway (Fig. 3B). These results were also confirmed at
protein level, as shown by Western blot in Figure 3C. HS5 cells were
treated up to 24 h with 20 or 50 lg/ml of LAMA84" exosomes and
with LAMA84" exosomes plus gefitinib; LAMA84" exosomes
increase the expression of SNAIL with the maximum effect at 3 h and
Fig. 1 Exosomes isolated from LAMA84 cells and CML patient cells con-
tain amphiregulin. (A) Total proteins were extracted from LAMA84 cells,
LAMA84" exosomes (exo) and conditioned medium of cells deprived
of exo (c.m.–exo) and were subjected to Western blot analysis with
antibody against AREG. LAMA84" exosomes are enriched with epider-
mal growth factor receptor (EGFR) ligand, AREG. (B) Analysis, by real-
time PCR, of AREG mRNA levels from CD34+ cells, as control, and from
cells of 13 different CML patients. Sixty-two per cent of these patients
showed an increase in AREG mRNA expression. Levels of the target
transcript were normalized to a GAPDH endogenous control. Final val-
ues were expressed as fold of induction. (C) Total proteins were
extracted from cells of CML patients n°8 and n°13 and from exosomes
isolated from serum of the same CML patients and were subjected to
Western blot analysis with antibody against AREG. The protein is found
both in lysates from cell patients (patient’s cell lysate) and in lysates
from exosomes isolated from patient’s serum (patient’s exosomes).
AREG, amphiregulin; CML, chronic myelogenous leukaemia.
4 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
gefitinib reverts the effects observed. Data were confirmed by treat-
ment of HS5 stromal cells for 3 h with neutralizing antibody anti-
AREG (Ab Areg) in combination or not with LAMA84" exosomes
(50 lg/ml). Figure 3D shows that the treatment of cells with Ab Areg
reduces the exosomal-induced expression of Snail. These data
demonstrate that (i) LAMA84" exosomes increase Snail expression
both at mRNA and at protein level in HS5 stromal cells and (ii) gefi-
tinib, as well as the neutralizing antibody to AREG, reverts the effects
mediated by exosomes. Moreover, we demonstrated that LAMA84"
exosomes exert the same effects on bone marrow primary stromal
cells, as shown in Figure S3B and E.
LAMA84" exosomes increase the expression of
IL8 and MMP9 in HS5 stromal cells and in bone
marrow primary stromal cells
We demonstrated that LAMA84" exosomes carrying AREG activate
EGFR on stromal cells, thus inducing the downstream signalling and
in particular the expression of SNAIL (Fig. 3). IL8 and MMP9 are two
known genes that are regulated by Snail. Figure 4A and B shows, by
real-time PCR at 6 h, that the treatment of HS5 cells with LAMA84"
exosomes induces a significative dose-dependent increase in IL8
Fig. 2 LAMA84" exosomes increase EGFR phosphorylation in HS5 stromal cells and in bone marrow primary stromal cells. Total proteins were extracted
from HS5 cells or BMSCs treated for 30 min. with different conditions were subjected to Western blot analysis with antibody against EGFR and pEGFR. The
numbers represent the values of densitometric analysis of EGFR and pEGFR levels, normalized versus b-actin, used as loading control. The histogram below
represents the ratio pEGFR/EGFR, based on densitometric analysis. Results from three independent experiments are shown. (A) HS5 treated or not with
LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib. (B) HS5 treated or not with recombinant Areg (Rh Areg 10 ng/ml) or LAMA84" exosomes (50 lg/
ml). (C) BMSC treated or not with LAMA84" exosomes (50 lg/ml) # 30 lM gefitinib. (D) HS5 treated or not with LAMA84" exosomes (50 lg/ml) #
30 lM erlotinib. AREG, amphiregulin; BMSC, bone marrow primary stromal cells; EGFR, epidermal growth factor receptor.
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(Fig. 4A) and MMP9 (Fig. 4B) expression; data were confirmed at
protein level with a dose-dependent increase in IL8 and MMP9 at
24 h, demonstrated by ELISA (IL8 and MMP9, Fig. 4C and D) and by
Western blot (MMP9, Fig. 4E). To confirm the involvement of EGFR
signalling, addition of gefitinib to HS5 cells reverts the effects
observed both at mRNA and at protein level. Moreover, we demon-
strated that LAMA84" exosomes exert the same effects on bone
marrow primary stromal cells, as shown in Figure S3A, C, D and E. In
conclusion, we showed here that the increase in the expression of IL8
and MMP9, induced by addition of LAMA84" exosomes, is mediated
by EGFR pathway. To confirm the essential role of Snail in EGFR sig-
nalling, we also used small-interfering RNAs (siRNAs) to knock down
Snail expression in HS5 cells. Transfection of HS5 with Snail siRNA
caused, as expected, a striking reduction in both IL8 (Fig. 5A) and
MMP9 (Fig. 5B) mRNA levels compared with HS5 transfected with
scramble siRNA. These results confirmed the central role of Snail in
regulating IL8 and MMP9 expression.
Treatment of HS5 with LAMA84" exosomes
increases LAMA84 cell adhesion to stromal
monolayer through the expression of annexin A2
In the bone marrow microenvironment, the bidirectional cell–cell
crosstalk between leukaemic and stromal cells is mediated by soluble
cytokines and cell–cell adhesion. Figure 6A shows that the pre-treat-
Fig. 3 LAMA84" exosomes increase Snail expression in HS5 stromal cells. Analysis, by real-time PCR, of Snail mRNA levels from HS5 treated with
50 lg/ml of LAMA84" exosomes for different times (A) or HS5 treated for 1 h with LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib (B).
LAMA84" exosomes induce a significative increase in Snail at 1 h, and gefitinib reverts this effect. Levels of the target transcript were normalized to
GAPDH as endogenous control. Final values were expressed as fold of induction. Results from three independent experiments are shown. **P < 0.01.
Total proteins were extracted from HS5 cells and HS5 treated for 3–6–24 h with LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib (C) and
LAMA84" exosomes plus neutralizing antibody anti-AREG (previously incubated for 2 h at 37°C; (D) and were subjected to Western blot analysis with
antibody against SNAIL. LAMA84" exosomes induce an increase in SNAIL in a dose-dependent manner; co-treatment of LAMA84" exosomes and Ab
AREG partially reverts this effect confirming the involvement of AREG. The numbers represent the values of densitometric analysis of SNAIL, normalized
versus b-actin, used as loading control. Results from three independent experiments are shown. AREG, amphiregulin.
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ment of HS5 for 24 h with LAMA84 exosomes increases the adhesion
of LAMA84 cells to stromal monolayer, as previously demonstrated
[12]. Gefitinib reverts the effect of LAMA84" exosomes treatment in
CML cell adhesion to HS5 monolayer, thus indicating the involvement
of EGFR pathway in the adhesion of leukaemic cells to stromal cells.
Recently, it has been demonstrated that annexin A2, expressed on
stromal cells, regulated bone marrow homing of Multiple Myeloma
cells supporting their growth and regulating their adhesion to stromal
cells [27]. To determine whether annexin A2 is involved in our
system, we treated HS5 cells with LAMA84 exosomes for 24 h; as
shown in Figure 6B, LAMA84 exosomes induce a significative
increase in annexin A2 mRNA expression, and data were confirmed at
protein level as shown in Figure 6C. Treatment with Gefitinib reverts
the effect of LAMA84 exosomes treatment both for annexin A2 mRNA
and protein level, suggesting a regulation of annexin A2 by EGFR.
We, therefore, conclude that EGFR plays a critical role in adhesion
of leukaemic cells to stromal cells, and we suggest that this adhesion
pathway could be mediated by the increase in annexin A2 expression
in stromal cells.
Discussion
In these recent years, the scientific community has focused the atten-
tion on the role of the tumour microenvironment and intercellular
communication between cancer cells and normal stromal cells. In this
context, a number of studies investigated the role played by cancer
cell–derived exosomes as cargos of cytokines, growth factors, mRNA
and miRNAs in the modulation of tumour progression [7,8]. Exo-
somes are now considered as signalling organelles that have been
demonstrated to affect growth, invasion, angiogenesis and metastatic
niche formation [9].
We previously demonstrated that leukaemic and stromal cells
establish a bidirectional crosstalk; CML exosomes induce the produc-
tion and release of IL8 from stromal cells that in turn sustains the
growth and survival of CML cells both in vitro and in vivo [12]. The
results shown herein suggest a possible mechanism through which
CML exosomes cause increased release of IL8 from stromal cells.
The EGFR is a signal transducer that has been highly conserved dur-
ing evolution and plays an important role in different physiological
Fig. 4 LAMA84" exosomes increase the expression of IL8 and MMP9 in HS5 stromal cells. Analysis, by real-time PCR, of IL8 (A) and MMP9 (B)
mRNA expression from HS5 treated for 6 h with LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib. Levels of the target transcript were nor-
malized to GAPDH as endogenous control. Final values were expressed as fold of induction. The conditioned medium of HS5, treated for 12–24 h
with LAMA84" exosomes, was used for IL8 ELISA (C) or MMP9 ELISA (D). Total proteins were extracted from HS5 cells and HS5 treated for 24 h
with LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib and were subjected to Western blot analysis with antibody against MMP9; b-actin was
used as loading control (E). LAMA84" exosomes induce a significative increase in IL8 and MMP9 (mRNA and protein) and gefitinib reverts this
effects. Results from three independent experiments are shown. *P < 0.05; **P < 0.01.
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processes, such as cell proliferation, cell migration, angiogenesis and
apoptosis.
A number of studies have demonstrated that in vitro treatment
of mesenchymal stem cells with epidermal growth factor, HBEGF,
AREG or TGFa induces growth factor production [28,29] [14] that
may also affect malignant phenotypes such as cancer cell prolifera-
tion and metastasis [30–31]. Among EGFR ligands, amphiregulin,
even if has lower binding affinity for EGFR than EGF or TGFa, is
highly expressed in different tumours, such as breast cancer or
hepatocellular carcinoma, contributing to the transformed pheno-
type [17,18]. AREG activates signalling in an autocrine manner in
tumour cells, but it is also able to activate EGFR via paracrine sig-
nals from non-resident cells of the microenvironment [21]. Singh
and Coffey recently described a new extracrine (exosomal targeted
receptor activation) signalling that involves the packaging and
release of EGFR ligands via exosomes [19], and Coffey’s group
demonstrated that tumour exosomes, carrying the EGFR ligand
AREG, are rapidly internalized in recipient human breast and colon
cancer cells leading to cancer cell invasion [20].
We speculate that a similar mechanism could occur in bone
marrow microenvironment and that AREG is involved in the activa-
tion of EGFR downstream signalling in mesenchymal stromal cells
leading to the expression and release of IL8 and other downstream
targets. We have shown that AREG found in LAMA84" exosomes
activates EGFR signalling in human stromal cells through a para-
crine mechanism and that gefitinib, a specific inhibitor of EGFR
activation, or neutralizing antibody anti-AREG may revert the
effects mediated by LAMA84" exosomes. Importantly, exosomes
isolated from serum of CML patients carry AREG, thus confirming
the role of AREG–EGFR axis mediated by CML exosomes, also
in vivo.
EGFR downstream signalling, involved in cell–cell communication
and tumour progression, is known to lead to the regulation of gene
expression through the transcriptional factor SNAIL [25,26]. SNAIL
expression has been linked, in several experimental systems, to a
change in cell morphology and invasive properties of the cells.
Although SNAIL is widely expressed in early development, in adult
animals it is limited to a subset of mesenchymal cells, where it has a
Fig. 5 SNAIL siRNA inhibits IL8 and
MMP9 mRNA expression from HS5 cells.
IL8(A) and MMP9 (B) mRNA expression
levels were evaluated in HS5 transfected
with scramble siRNA (siScramble) or with
Snail siRNA (siSnail). Transfection of HS5
with Snail siRNA reduced IL8 and MMP9
mRNA levels compared with control (ctrl).
Levels of the target transcript were nor-
malized to GAPDH as endogenous control.
Final values were expressed as fold of
induction. Results from three independent
experiments are shown. *P < 0.05.
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largely unknown function. Batle et al. demonstrated in vivo that
SNAIL is required to maintain MSCs, and this effect is associated to
the responsiveness to TGF-b1 [32].
It is well known that SNAIL induces the expression of different tar-
gets, such as MMPs, and directly regulates IL8 expression. Moreover,
the SNAIL/IL8 axis plays a critical role in colorectal cancer stemness
and malignancy, thus suggesting that IL8 may function as a signifi-
cant regulatory factor within the tumour microenvironment [33]. The
data present herein showed that the EGFR signalling, activated in
stromal cells by CML exosomes, induces the downstream expression
of SNAIL and consequently the increase in SNAIL targets, MMP9 and
IL8. We further confirmed, through the use of short-interfering RNAs,
the involvement of SNAIL in CML exosomes-mediated EGFR sig-
nalling in mesenchymal stromal cells.
Our previous work demonstrated that CML exosomes, through the
increase in IL8, promote leukaemia cell adhesion on HS5 stromal cells
[12]. It is well known that EGFR modulates several steps of cancer pro-
gression and one of the first steps is adhesion of cancer cells to the
non-tumour cells in the microenvironment. For this reason, we decide
to investigate the possible role of EGFR pathway in the adhesion of CML
cells to stromal monolayer. We confirmed here that pre-treatment of
HS5 with LAMA84 exosomes increases the adhesion of leukaemic cells
Fig. 6 Treatment of HS5 with LAMA84" exosomes increase the LAMA84 cell adhesion to stromal monolayer through the expression of annexin A2.
(A) For the adhesion assay, HS5 monolayer was treated for 24 h with LAMA84" exosomes (50 lg/ml) # different doses of gefitinib (1–5–10 lM);
after 24 h, LAMA84 cells were added to the different monolayers and were left to adhere for 3.5 h. Pre-treatment of HS5 monolayer with LAMA84"
exosomes promotes the adhesion of chronic myelogenous leukaemia (CML) cells to stromal cells. Gefitinib reverts this effect. Results from three
independent experiments are shown. *P < 0.05; **P < 0.01; ***P < 0.001. (B) Analysis, by real-time PCR, of annexin A2 mRNA expression from
HS5 treated for 24 h with LAMA84" exosomes (50 lg/ml) # 30 lM gefitinib. LAMA84" exosomes induce a significative increase in annexin A2
mRNA expression and gefitinib reverts this effect. Levels of the target transcript were normalized to GAPDH as endogenous control. Final values
were expressed as fold of induction. Results from three independent experiments are shown. **P < 0.01. (C) Total proteins were extracted from
HS5 cells and HS5 treated for 24 h with LAMA84" exosomes (20–50 lg/ml) # 30 lM gefitinib and were subjected to Western blot analysis with
antibody against annexin A2. LAMA84" exosomes induce an increase in annexin A2 in a dose-dependent manner, and co-treatment of LAMA84"
exosomes and gefitinib partially reverts this effect confirming the involvement of epidermal growth factor receptor (EGFR). Numbers represent the
values of densitometric analysis of annexin A2 levels, normalized versus b-actin, used as loading control. Results from three independent
experiments are shown.
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to the stromal monolayer; moreover, the treatment with gefitinib reverts
these effects, confirming a possible role of EGFR in regulating leukaemic
cells adhesion inside the tumour microenvironment of CML.
We investigated the molecules involved in the cell–cell adhesion.
Accumulating evidence suggests that annexin A2 is involved in vari-
ous cellular activities, including cell proliferation, adhesion, migration,
invasion and angiogenesis and its overexpression was observed in
many types of tumour tissues thus contributing to cancer progression
[34, 35]. Annexin A2 interacts with several signalling proteins, regula-
tors/effectors of the EGFR/Ras pathway, such as Src tyrosine kinases,
Rho, Cdc42, Ras and GTPase activating protein (GAP), thus indirectly
modulating EGFR/Ras signalling [36, 37]. Grewal and Enrich
described annexins as modulators of EGF receptor signalling and traf-
ficking [38]. In addition to its expression in cancer cells, annexin A2
is expressed by other cell types found in tumour microenvironment,
thus contributing to cancer progression. For example, Shiozawa et al.
demonstrated that annexin A2, expressed on bone marrow cells, is
involved in stem cell homing mechanisms necessary for prostate can-
cer cells to gain access to the niche [39]; recently, it has been shown
that annexin A2–CXCL12 interactions regulate metastatic prostate
cancer cell targeting and their growth in the bone marrow [40]. Fur-
thermore, it has been recently demonstrated that annexin A2,
expressed on stromal cells, regulates bone marrow homing of Multi-
ple Myeloma cells supporting their growth, through the activation of
ERK ½ and AKT, and regulating their adhesion to stromal cells [23].
Interestingly, Seckinger’s group demonstrated that annexin A2
expression in primary myeloma cells is an adverse prognostic factor
[41] and an increased expression of annexin A2 has been also
reported as a poor prognostic factor for solid tumours such as pan-
creatic and breast cancer [42, 43]. We demonstrated that pre-treat-
ment of HS5 with LAMA84" exosomes increases the expression of
annexin A2 at mRNA and protein level and the adhesion of leukaemic
cells to the stromal monolayer. Gefitinib reverts these effects, con-
firming a possible role of EGFR in regulating cancer cell adhesion.
Briefly, we have shown here a possible mechanism through which, in
the context of the bidirectional crosstalk between bone marrow–
derived stromal and leukaemic cells, CML exosomes exert their effect
on tumour microenvironment. The involvement of EGFR signalling in
this crosstalk and the regulation of growth and survival mediated by
Snail and annexin A2 provides a new piece in the understanding of
the role of exosomes in this crosstalk and has significant implications
for new therapeutic approaches for early diagnosis of leukaemia.
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